Addressing Knowledge and Practice Gaps in Changing Paradigms of Dermatological Inflammatory Conditions RFP

Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Wednesday 10th, April 2024

External Deadline: Monday 15th, April 2024


Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Specific Area of Interest:  Projects that will be considered for Pfizer support will focus on educational programs addressing knowledge and practice gaps specific to the overall care management of atopic dermatitis (AD), Alopecia Areata (AA), or Vitilgo. We are particularly interested in programs that focus on some or all of the following:

  • – Programs on Advances in AD, AA, or Vitiligo
  • – Educational patient tools, pictograph-based and plain language, or videos for AD, AA, or Vitiligo disease state, disease management or advanced therapies
  • – Educational programs for Primary Care Providers (General Practitioners, allied Health care providers including Nurse practitioners, nurses, Registered pharmacists and medical students) as well as other specialists involved in the treatment of these patients like allergists or pediatricians.
  • – Programs focusing on mental health for AA- AD- Vitiligo patients, or on specific management of patients with skin of color suffering from inflammatory dermatological conditions.

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Sue Lee, Grant Officer (

Date RFP Issued: January 22, 2024

Geographic Scope: Canada

Clinical Area:  Dermatology: Atopic Dermatitis (AD), Alopecia Areata (AA), or Vitiligo

Link to full RFP: Addressing Knowledge and Practice Gaps in Changing Paradigms of Dermatological Inflammatory Conditions

Application Due Date: April 15, 2024

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: January 24, 2024